Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma

R. Bonacci; A. Gigliotti; E. Baudin; N. Wion-Barbot; P. Emy; M. Bonnay; A. F. Cailleux; I. Nakib; M. Schlumberger

doi:10.1038/bjc.1998.530

Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma

R. Bonacci, A. Gigliotti, E. Baudin, N. Wion-Barbot, P. Emy, M. Bonnay, A. F. Cailleux, I. Nakib, M. Schlumberger

Research output: Contribution to journal › Article › peer-review

71 Citations (Scopus)

Abstract

Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m^-2 day^-1 on days 1-3) and cisplatin (100 mg m^-2 day^-1 on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels > 14 mg l^-1. Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.

Original language	English
Pages (from-to)	546-549
Number of pages	4
Journal	British Journal of Cancer
Volume	78
Issue number	4
DOIs	https://doi.org/10.1038/bjc.1998.530
Publication status	Published - 1 Jan 1998

Keywords

Adrenal cortical carcinoma
Cisplatin
Etoposide
Mitotane

Access to Document

10.1038/bjc.1998.530

Cite this

@article{b5a115883aa446d3a17f21e22d845d81,

title = "Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma",

abstract = "Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m-2 day-1 on days 1-3) and cisplatin (100 mg m-2 day-1 on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels > 14 mg l-1. Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.",

keywords = "Adrenal cortical carcinoma, Cisplatin, Etoposide, Mitotane",

author = "R. Bonacci and A. Gigliotti and E. Baudin and N. Wion-Barbot and P. Emy and M. Bonnay and Cailleux, {A. F.} and I. Nakib and M. Schlumberger",

year = "1998",

month = jan,

day = "1",

doi = "10.1038/bjc.1998.530",

language = "English",

volume = "78",

pages = "546--549",

journal = "British Journal of Cancer",

issn = "0007-0920",

number = "4",

}

TY - JOUR

T1 - Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma

AU - Bonacci, R.

AU - Gigliotti, A.

AU - Baudin, E.

AU - Wion-Barbot, N.

AU - Emy, P.

AU - Bonnay, M.

AU - Cailleux, A. F.

AU - Nakib, I.

AU - Schlumberger, M.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m-2 day-1 on days 1-3) and cisplatin (100 mg m-2 day-1 on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels > 14 mg l-1. Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.

AB - Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m-2 day-1 on days 1-3) and cisplatin (100 mg m-2 day-1 on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels > 14 mg l-1. Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.

KW - Adrenal cortical carcinoma

KW - Cisplatin

KW - Etoposide

KW - Mitotane

UR - http://www.scopus.com/inward/record.url?scp=0031827589&partnerID=8YFLogxK

U2 - 10.1038/bjc.1998.530

DO - 10.1038/bjc.1998.530

M3 - Article

C2 - 9716042

AN - SCOPUS:0031827589

SN - 0007-0920

VL - 78

SP - 546

EP - 549

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 4

ER -

Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma

Abstract

Keywords

Access to Document

Other files and links

Cite this